Sign In
Buy FULC
$3.58
-0.140 (-3.76%)
At Close: Jul 31, 2026
Fulcrum Therapeutics: Multiple Interesting Programs, Needs A Better Entry Point
01:24am, Friday, 03'rd Sep 2021
Fulcrum Therapeutics: Multiple Interesting Programs, Needs A Better Entry Point
2 Soaring Biotech Stocks With More Fuel in the Tank
06:47am, Monday, 23'rd Aug 2021
These recent winners still have a long way to run.
Fulcrum Therapeutics Announces Pricing of $125 Million Public Offering of Common Stock
10:09pm, Wednesday, 11'th Aug 2021
CAMBRIDGE, Mass., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically de
Why Fulcrum Therapeutics Popped Again on Tuesday
04:06pm, Wednesday, 11'th Aug 2021
Compelling clinical-trial data that could validate the company's unique approach to new drug development inspired a slew of analyst upgrades.
Why Are Fulcrum Therapeutics Shares Trading Higher Today?
09:55am, Wednesday, 11'th Aug 2021
Fulcrum Therapeutics Inc (NASDAQ:FULC) is trading higher again Wednesday after the stock saw positive analyst coverage following the company's better-than-expected financial results and announcement
FULC Stock Price Increased 125.33%: Why It Happened
07:48am, Wednesday, 11'th Aug 2021
The stock price of Fulcrum Therapeutics Inc (NASDAQ: FULC) increased 125.33%. This is why it happened.
Fulcrum Therapeutics Announces Proposed Public Offering of Common Stock
04:24pm, Tuesday, 10'th Aug 2021
CAMBRIDGE, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically d
Why Fulcrum Therapeutics Shares Are Soaring Today
01:29pm, Tuesday, 10'th Aug 2021
Fulcrum Therapeutics Inc (NASDAQ: FULC) is surging higher Tuesday after the company reported results from its Phase 1 study of FTX-6058 for sickle cell disease showed proof of mechanism and proof of
Fulcrum Therapeutics, Inc. (FULC) CEO Bryan Stuart on Q2 2021 Results - Earnings Call Transcript
12:54pm, Tuesday, 10'th Aug 2021
Fulcrum Therapeutics, Inc. (FULC) CEO Bryan Stuart on Q2 2021 Results - Earnings Call Transcript
Here's Why Fulcrum Therapeutics Stock Is Shooting Higher Today
10:56am, Tuesday, 10'th Aug 2021
A positive trial readout suggests the company's new drug discovery engine has more potential than expected.
FULC Stock Price Increases Over 60% Pre-Market: Why It Happened
09:13am, Tuesday, 10'th Aug 2021
The stock price of Fulcrum Therapeutics Inc (NASDAQ: FULC) increased by over 60% pre-market. This is why it happened.
Fulcrum Therapeutics Reports Recent Business Highlights and Second Quarter 2021 Financial Results
07:01am, Tuesday, 10'th Aug 2021
– Reported positive interim results from ongoing Phase 1 trial in healthy adult volunteers with FTX-6058 for sickle cell disease demonstrating proof of mechanism and proof of biology –
Will Fulcrum Therapeutics, Inc. (FULC) Report Negative Q2 Earnings? What You Should Know
04:47pm, Tuesday, 03'rd Aug 2021
Fulcrum Therapeutics, Inc. (FULC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CAMBRIDGE, Mass., June 24, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically
Fulcrum Therapeutics, Evofem Biosciences Drug Candidates Receive FDA Fast Track Designation
04:19pm, Wednesday, 12'th May 2021
The FDA has granted Fast Track designation to Fulcrum Therapeutics Inc's (NASDAQ: FULC) losmapimod for the potential treatment of facioscapulohumeral muscular dystrophy (FSHD). Fulcrum is on trac
